Digital PCR-Based Method for Detecting CDKN2A Loss in Brain Tumours
DiscussionThe method presented can give a fast, cost-effective, clinically reliable evaluation ofCDKN2A loss in tissue with more than 50% tumour content. Its ability to work with old samples and with low amounts of DNA makes it the favoured assay in cases where other techniques fail.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
More News: Astrocytoma | Brain | Brain Tumor | Genetics | Glioma | Information Technology | Molecular Biology | Neurology | Pathology